FMC, Micropep Technologies In Deal To Co-develop Bioherbicide Solutions

FMC Corp. (FMC), an agricultural sciences company, announced Tuesday a strategic collaboration with Micropep Technologies, a micropeptide technology company, to develop biological solutions to control destructive herbicide-resistant weeds that reduce crop yields. The companies did not disclose the specific terms of the agreement.

The partnership is expected to accelerate the ongoing development of natural weed control products based on short protein molecules naturally produced by plant cells.

Under an exclusive multi-year deal, the companies will focus on developing new solutions for controlling key herbicide-resistant weeds in corn and soybeans.

They will combine their respective R&D capabilities leveraging Micropep's technology to expedite and improve the success rate in identifying innovative biological herbicides.

In the deal, the companies seek to develop a selective natural herbicide effective in controlling major resistant weeds by combining Micropep's proprietary AI-powered micropeptide discovery platform with FMC's strong scientific and commercial capabilities.

Kathleen Shelton, FMC executive vice president and chief technology officer, said, "We are pleased to collaborate with Micropep in developing novel micropeptide technology to address resistance management. These novel mode-of-action biomolecules in agriculture represent an exciting new frontier; this is a completely new solution compared to what is available to growers today."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT